mdma | CARLAT PUBLISHING

CARLAT WEBINAR

Carlat Psychiatry News - Stimulant Fraud • Oral Ketamine • E-Cigarettes • Benzo Tapering • CBD

September 17, 2024

Chris Aiken, MD, Greg Malzberg, MD, and Kellie Newsome, PMHNP

0.25 CME Credits. In this episode, we explore nine groundbreaking stories in mental health and psychiatric medicine, covering everything from healthcare fraud to the latest advancements in drug trials. First, we dive into the recent charges brought by the US Department of Justice against executives at Done, a California-based telehealth company, for alleged healthcare fraud. Done is accused of prescribing over 40 million Adderall pills to patients without proper evaluation, raising concerns about the balance between increasing mental healthcare access and responsible prescribing practices.

MDMA: What Went Wrong Part 2

June 17, 2024

Chris Aiken, MD and Kellie Newsome, PMHNP

Did boundary violations sink MDMA-assisted therapy, or was there something more? In part II of our series, we look at what else went wrong.

MDMA: What Went Wrong Part 1

June 10, 2024

Chris Aiken, MD

Did boundary violations sink MDMA assisted psychotherapy? We explore the reasons behind the FDA panel’s rejection of this psychedelic therapy.

Expert Q&A

Psychedelics and Addiction

April 1, 2024

Snehal Bhatt, MD

Snehal Bhatt, MD.

Chief, Addiction Psychiatry; Professor, Psychiatry and Behavioral Sciences, University of New Mexico, Albuquerque, NM.

Dr. Bhatt has no financial relationships with companies related to this material.

Dr. Bhatt outlines the latest developments in therapeutic uses of psychedelic medications. He highlights the great opportunities as well as the potential drawbacks. He details some of his own work in the use of psilocybin for the treatment of alcohol use disorder and advises clinicians how to discuss psychedelics with their patients.

Expert Q&A

Psychedelic-Assisted Psychotherapy

June 1, 2023

Jeffrey Guss, MD

Jeffrey Guss, MD.

Psychiatrist and psychoanalyst. Clinical Assistant Professor of Psychiatry at NYU Grossman School of Medicine. Faculty at the NYU Postdoctoral Program in Psychotherapy and Psychoanalysis.

Dr. Guss has no financial relationships with companies related to this material.

What actually happens during psychedelic psychotherapy? Dr. Guss walks us through the steps.
1) preparation, 2) dosing, and 3) integration, where the insights gained from psychedelic experiences are turned into action in the real world.

Clinical Update

A Psychedelic Primer

June 1, 2023

Chris Aiken, MD and Garrett Rossi, MD.

Chris Aiken, MD. Editor-in-Chief of The Carlat Psychiatry Report. Assistant Professor, NYU Langone Department of Psychiatry. Practicing psychiatrist, Winston-Salem, NC.

Garrett Rossi, MD. Inpatient/Consult Attending Psychiatrist, AtlantiCare Regional Medical Center, Pomona, NJ.

The authors have no financial relationships with companies related to this material.

How did a dangerous drug of abuse become a therapeutic panacea?

MDMA-Assisted Therapy for Severe PTSD

January 31, 2022

Michael Posternak, MD.

Michael Posternak, MD. Dr. Posternak has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

MDMA is being repurposed as part of drug-assisted psychotherapy for PTSD, and this trial will help determine whether it gains FDA approval for that use.